Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPAP: C14 for HR-HPV and Cervical Lesions
NCT06672653Phase 2Not yet recruiting
- Sponsor
- MGB Biopharma
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zinc tetra-ascorbo-camphorate in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by MGB Biopharma. Primary endpoint: Genital HR-HPV Viral Load at 16 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
zinc tetra-ascorbo-camphorate
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06672653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672653.